JP2015528454A5 - - Google Patents

Download PDF

Info

Publication number
JP2015528454A5
JP2015528454A5 JP2015529009A JP2015529009A JP2015528454A5 JP 2015528454 A5 JP2015528454 A5 JP 2015528454A5 JP 2015529009 A JP2015529009 A JP 2015529009A JP 2015529009 A JP2015529009 A JP 2015529009A JP 2015528454 A5 JP2015528454 A5 JP 2015528454A5
Authority
JP
Japan
Prior art keywords
vegf antagonist
medicament
administered
antibody
medicament according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015529009A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015528454A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/067846 external-priority patent/WO2014033184A1/en
Publication of JP2015528454A publication Critical patent/JP2015528454A/ja
Publication of JP2015528454A5 publication Critical patent/JP2015528454A5/ja
Pending legal-status Critical Current

Links

JP2015529009A 2012-08-28 2013-08-28 眼血管増殖性疾患の処置におけるｖｅｇｆアンタゴニストの使用 Pending JP2015528454A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261693913P 2012-08-28 2012-08-28
US61/693,913 2012-08-28
PCT/EP2013/067846 WO2014033184A1 (en) 2012-08-28 2013-08-28 Use of a vegf antagonist in treating ocular vascular proliferative diseases

Publications (2)

Publication Number Publication Date
JP2015528454A JP2015528454A (ja) 2015-09-28
JP2015528454A5 true JP2015528454A5 (enExample) 2016-11-24

Family

ID=49083670

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015529009A Pending JP2015528454A (ja) 2012-08-28 2013-08-28 眼血管増殖性疾患の処置におけるｖｅｇｆアンタゴニストの使用

Country Status (4)

Country Link
US (1) US20150297675A1 (enExample)
EP (1) EP2890389A1 (enExample)
JP (1) JP2015528454A (enExample)
WO (1) WO2014033184A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007237096C1 (en) 2006-04-07 2012-12-13 EyePoint Pharmaceuticals, Inc. Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof
EP3505182A1 (en) 2011-10-13 2019-07-03 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
JP2016522250A (ja) * 2013-06-20 2016-07-28 ノバルティス アーゲー 黄斑浮腫の治療におけるｖｅｇｆアンタゴニストの使用
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
TWI799366B (zh) * 2015-09-15 2023-04-21 美商建南德克公司 胱胺酸結骨架平臺
RU2018121813A (ru) * 2015-11-18 2019-12-19 Формикон Аг Предварительно заполненный пластиковый шприц, содержащий антагонист vegf
ES2903397T3 (es) 2015-12-30 2022-04-01 Marshall Univ Research Corporation Composiciones y métodos para tratar la retinopatía
CA3010056A1 (en) * 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
US10576128B2 (en) * 2016-01-26 2020-03-03 Formycon Ag Liquid formulation of a VEGF antagonist
TW201904610A (zh) 2017-06-14 2019-02-01 德商拜耳製藥公司 用於治療新生血管型青光眼之非抗體vegf拮抗劑
CN111356471A (zh) * 2017-11-20 2020-06-30 济世发展生物药业有限公司 包含赖氨酸盐作为张力调节剂的阿柏西普制剂及其用途
CN112203679A (zh) 2018-03-02 2021-01-08 科达制药股份有限公司 Il-6抗体及其融合构建体和缀合物
CN111867631A (zh) * 2018-03-16 2020-10-30 诺华股份有限公司 治疗眼部疾病的方法
KR102038008B1 (ko) * 2018-04-03 2019-10-29 주식회사 루트로닉 안과용 치료장치 및 이의 제어방법
EP3856245A4 (en) 2018-09-24 2022-10-26 EyePoint Pharmaceuticals, Inc. MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - ß (VE-PTP) AND VEGF
US20220370460A1 (en) * 2019-09-13 2022-11-24 Aldeyra Therapeutics, Inc. Ophthalmic formulations of methotrexate
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
JP2023529203A (ja) 2020-06-11 2023-07-07 ジェネンテック， インコーポレイテッド ナノリポタンパク質－ポリペプチドコンジュゲート並びにそれを使用する組成物、システム、及び方法
WO2023019216A2 (en) * 2021-08-13 2023-02-16 The Board Of Trustees Of The Leland Stanford Junior University Methods for diagnosing and treating ischemic eye disease
US11911385B1 (en) 2022-12-14 2024-02-27 Aldeyra Therapeutics, Inc. Methotrexate treatment methods

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ534310A (en) * 2002-02-07 2008-03-28 Novozymes Delta Ltd Albumin-fused anti-angiogenesis peptides
US7399612B2 (en) * 2003-06-30 2008-07-15 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
US11078262B2 (en) * 2007-04-30 2021-08-03 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
SG10201510586PA (en) * 2008-06-30 2016-01-28 Mesoblast Inc Treatment of Eye Diseases And Excessive Neovascularization Using A Combined Therapy
CN102272148A (zh) * 2008-11-03 2011-12-07 分子组合公司 抑制vegf-a受体相互作用的结合蛋白
CN102458471A (zh) * 2009-05-28 2012-05-16 葛兰素集团有限公司 用于治疗或预防眼病的TNFα拮抗剂和VEGF拮抗剂的组合
JPWO2012105610A1 (ja) * 2011-02-02 2014-07-03 株式会社三和化学研究所 眼内血管新生及び／又は眼内血管透過性亢進を伴う疾患の予防又は治療のための医薬

Similar Documents

Publication Publication Date Title
JP2015528454A5 (enExample)
WO2014033184A1 (en) Use of a vegf antagonist in treating ocular vascular proliferative diseases
JP2014532072A5 (enExample)
ME00591B (me) Upotreba dii4 antagonista kod ishemijske povrede ili vaskularne insuficijencije
JP2017537105A5 (enExample)
Peponis et al. Ocular side effects of anti-rheumatic medications: what a rheumatologist should know
JP5557408B1 (ja) 眼底疾患治療剤
KR102373289B1 (ko) 지속성 부종을 갖는 삼출성 노인성 황반변성을 치료하기 위한 시롤리무스의 용도
JP2017525769A5 (enExample)
JP2012505162A5 (enExample)
Fang et al. Efficacy and safety of one intravitreal injection of bevacizumab in diabetic macular oedema
Tomomatsu et al. Comparative study of combined bevacizumab/targeted photocoagulation vs bevacizumab alone for macular oedema in ischaemic branch retinal vein occlusions
CN114306575A (zh) 具有小的活动性脉络膜新生血管病变的年龄相关性黄斑变性的治疗
PH12020551015A1 (en) Medicine for preventing or treating ophthalmic disease associated with enhanced intraocular neovascularization and/or intraocular vascular permeability
US11478465B2 (en) Compounds for treatment of eye diseases associated with excessive vascularisation
WO2015135306A1 (zh) 青蒿素及其衍生物在制备防治眼科血管性疾病药物中的应用及药物组合物
JP2017523974A5 (enExample)
JP2016516761A5 (enExample)
JP2020523307A5 (enExample)
US20170224815A1 (en) Method of Preventing and Treating Retinal Microvasculature Inflammation Using C-Met Signaling Pathway Inhibition
Koo et al. Resolution of macular edema after systemic treatment with furosemide
KR20160013026A (ko) 폴립양 맥락막 혈관병증의 치료
SHARM et al. Clinical Utilisation of Bevacizumab and Patient Monitoring in Retinal Vein Occlusion and Diabetic Macular Edema
Tataru et al. Evaluation of the efficacy and safety of intravitreal bevacizumab for macular edema related to retinal vein occlusion
WO2014055054A1 (ru) Применение 1-адамантилетилокси-з-морфолино - 2-пропанола или его фармацевтически приемлемых солей в фармацевтических композициях в качестве нейроретинопротектора